NCI Funds Range of Prostate Cancer Research

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 5
Volume 8
Issue 5

BETHESDA, Md-The National Cancer Institute is funding a wide range of prostate cancer research, including genetic epidemiology, molecular diagnostics, diet and nutrition, animal models, surveillance, diagnostic imaging, clinical trials, prevention and early detection, and the Cancer Genome Anatomy Project .

BETHESDA, Md—The National Cancer Institute is funding a wide range of prostate cancer research, including genetic epidemiology, molecular diagnostics, diet and nutrition, animal models, surveillance, diagnostic imaging, clinical trials, prevention and early detection, and the Cancer Genome Anatomy Project .

For a list of grant opportunities and contacts, visit the NCI’s website at www.nci.nih.gov/prostate.html.

Articles in this issue
Delirium Is Often Misdiagnosed in Advanced Cancer
Preop Chemo Recommended for Locally Advanced Disease
High Degree of Variability in HIV Testing Throughout the US
Physicians Need ‘Coherent Game Plan’ for Care of Dying
NCI Funds Pediatric Brain Tumor Consortium
Marketing Your Cancer Center to Today’s Savvy Consumers
Axillary Irradiation Can Replace Dissection in Some Breast Cancer’s
Dr. Bailes Urges Oncologists to Act Against APC Proposal
Elective Lymph Node Dissection Supported in Some Melanomas
Broad Coalition of Health Care Groups Opposes APCs
Depression and Anxiety Difficult to Diagnose in Cancer Patients
Tips on Distinguishing Good Metaanalyses From Poor Ones
How Patients Hear a Cancer Diagnosis Can Affect Long-Term QOL
Neoadjuvant Hormonal Therapy in Prostate Cancer: Pro and Con
Treating Patients on Protocol More Effective, No More Costly

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
1 expert in this video
1 expert in this video
1 expert in this video
Related Content
Chemoradiotherapy resulted in lower incidence of local progression, prompting an evaluation of resectability in patients with advanced gallbladder cancers.

Chemoradiation Prolongs OS, Maintains QOL in Advanced Gallbladder Cancers

Roman Fabbricatore
April 24th 2025
Article

Chemoradiotherapy resulted in lower incidence of local progression, prompting an evaluation of resectability in patients with advanced gallbladder cancers.

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;David Morris, MD, MS;Tanya B. Dorff, MD;Mark T. Fleming, MD
March 5th 2025
Podcast

A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.

Rad Onc First to Dose 177Lu in US, Notes Enormity of Recent mCRPC Approval

Rad Onc First to Dose 177Lu in US, Notes Enormity of Recent mCRPC Approval

Ariana Pelosci
April 17th 2025
Article

After the recent approval of 177Lu in PSMA+/mCPRCP prior to chemotherapy, Steven Finkelstein, MD, DABR, FACRO, highlights the importance of this milestone.

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Leveraging Artificial Intelligence Evolutions in Prostate Cancer Care

James B. Yu, MD, MHS, FASTRO;Julian C. Hong, MD, MS
July 1st 2024
Podcast

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

The phase 3 MIRAGE trial findings show that PROSTOX ultra was validated as a biomarker to predict genitourinary toxicity following SBRT.

PROSTOX ultra Reliably Predicts Long-Term Radiation AEs in Prostate Cancer

Roman Fabbricatore
April 9th 2025
Article

The phase 3 MIRAGE trial findings show that PROSTOX ultra was validated as a biomarker to predict genitourinary toxicity following SBRT.

Results from PSMAfore show that lutetium Lu 177 vipivotide tetraxetan elicited a median rPFS of 9.3 months vs 5.6 months with ARPI in prostate cancer.

FDA Approves Radioligand Therapy in PSMA–Positive, Castration-Resistant PC

Tim Cortese
March 28th 2025
Article

Results from PSMAfore show that lutetium Lu 177 vipivotide tetraxetan elicited a median rPFS of 9.3 months vs 5.6 months with ARPI in prostate cancer.